Minimally Invasive and Novel Therapeutics (MINT)
September 8-10, 2024
Fairmont Copley Plaza, Boston
138 St. James Avenue, Boston, MA 02116
Hybrid Course (offered In-person or online) &
optional hands on sessions
Course Directors:
Charudutt Paranjape, MD, MBBS, FACS
Kumar Krishnan, MD
The goal of the Minimally Invasive and Novel Therapeutics (MINT) course is to inform physicians on how best to incorporate these technologies into their practice. Using a video-based format, our goal is technique transfer from world-renowned faculty to the community, hospital, endoscopy suite, and operating room.
MINT offers an ideal mix of traditional standard-of-care principles with a balanced and unbiased view of new, cutting-edge information. This hybrid course (in-person and virtual) engages learners through video-based lectures with recordings of surgical and endoluminal therapies, along with lively multidisciplinary panel discussions, and hands-on training sessions in both endoluminal therapies and surgical techniques.
The annual hybrid Minimally Invasive and Novel Therapeutics (MINT) continuing medical education (CME) course, seeks to equip clinicians with advanced technical knowledge of the latest surgical and endoscopic procedures needed to diagnose and treat foregut disease utilizing novel educational formats such as video-based learning to encourage “technique transfer”.
We further hope to foster ongoing collaboration between gastroenterologists, surgeons, advanced practice providers, nurses, and dietitians to optimize the multidisciplinary care of patients with foregut digestive disease.
The annual conference is both in-person, with an optional hands-on component, and virtual live-streamed (and recorded).
Highlights for MINT 2024 include:
- Foregut disease
- Endoluminal/ flexible endoscopy Hands-on
- Robotic Hands-on
- Resident Robotic surgery hands-on and didactics
- Bariatric
- Pancreaticobiliary
- Hernia and abdominal wall
- MINT Multidisciplinary Team session
Learning Objectives
Upon completion of this activity, participants will be able to:
- Apply new knowledge in the management of patients with foregut disease, abdominal wall hernias, and pancreaticobiliary disease
- Develop treatment strategies based on current evidence and expert opinion
- Compare and contrast standard-of-care management with cutting-edge treatments
- Recognize the unique roles and contributions of various healthcare professionals within the multidisciplinary foregut team
- Collaborate effectively among multidisciplinary team members to improve patient outcomes
Who should attend:
Provider type: General surgeons, thoracic surgeons, gastroenterologists, nurse practitioners, physician assistants, nurses, dietitians
Physicians
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AMA PRA Category 1 Credits™
Mass General Brigham designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing
Mass General Brigham designates this activity for 16.75 ANCC contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.
AVAILABLE CREDIT
– 16.75 ABIM MOC II
– 16.75 ABS Accredited CME
– 16.75 AMA PRA Category 1 Credit™
– 16.75 Nursing Contact Hours
– 16.75 Participation